Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ4IKZ)

• Drug Name: RHIZOXIN Drug Info
• Synonyms: 90996-54-6; Rhizoxin from Rhizopus sp.

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 6437358
  ChEBI ID: CHEBI:72590
  CAS Number: CAS 90996-54-6
  TTD Drug ID: DMQ4IKZ

Molecule-Related Drug Atlas

Drug(s) Targeting Tubulin (TUB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Vinorelbine	DMVXFYE	Advanced cancer	2A00-2F9Z	Approved	[4]
Cabazitaxel	DMPAZHC	Breast cancer	2C60-2C65	Approved	[5]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[6]
Ixabepilone	DM2OZ3G	Breast cancer	2C60-2C65	Approved	[5]
Eribulin	DM1DX4Q	Breast cancer	2C60-2C65	Approved	[5]
Epothilon	DMITJRU	Ovarian cancer	2C73	Phase 3	[7]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
BMS-188797	DML1CK2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
Indibulin	DM6OFJ8	Advanced sarcoma	2A60-2C35	Phase 2	[10]

Drug(s) Targeting Tubulin beta (TUBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[11]
Albendazole	DMYZ57N	Echinococcus granulosus infectious disease		Approved	[12]
Vindesine	DMVR628	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[14]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[12]
Plinabulin	DMD7L48	Non-small-cell lung cancer	2C25.Y	Phase 3	[15]
Batabulin	DMHWE5R	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[16]
ABT-751	DMNG35S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[17]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[18]
BNC-105	DMJC8DR	Mesothelioma	2C51.2	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001808)
• [2] Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51.
• [3] Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
• [4] Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
• [7] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [8] Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
• [9] Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
• [10] 2011 Pipeline of ZioPharm.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
• [13] Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
• [14] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [15] NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
• [16] Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
• [17] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [18] Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
• [19] The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.